Growth potential Insulet’s Omnipod platform serves diabetes management with a tubeless, wearable insulin delivery system and automated delivery via Omnipod 5, which aligns with demand for convenient, needle-free solutions and could drive expansion into additional markets and adjacent conditions.

Global expansion With Omnipod availability in 25 countries, there is room to pursue partnerships with international distributors, payer collaborations, and localized regulatory strategies to accelerate market penetration and diversify revenue streams.

Integrated tech The product integrates with continuous glucose monitors and smartphone/controller interfaces, signaling a strong opportunity to upsell data services, analytics, and value-based care offerings to providers and health systems.

Sustain and scale Recent manufacturing and supply chain disclosures (including tubing issues) highlight the importance of robust quality assurance and proactive field support, presenting an opening for sales play focused on reliability improvements and service contracts.

Strategic partnerships Given positive first-quarter revenue growth and large-scale competitors, there is potential to pursue collaborations with major medical device ecosystems, payer programs, and digital health platforms to broaden adoption and drive co-branded solutions.